gsk201404176k4.htm
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending April 2014
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
-
 



 
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
 
I give below details of the following increases in interests in Ordinary Shares in GlaxoSmithKline plc purchased at a price of 1551.71 pence per Share on 11 April 2014, in respect of the personal holdings of the under-mentioned Director, Persons Discharging Managerial Responsibility (PDMR) and Connected Person following the re-investment of the dividend paid to shareholders on 10 April 2014.
 
 
 
Director/PDMR
 
 
 
Ordinary Shares
 
Connected Person
 
Ordinary Shares
Sir Andrew Witty
1,544.981
    
Dr M M Slaoui
316.782
-
  
Mr S Dingemans
713.791
    
Mr S M Bicknell
377.000
-
  
Mr R G Connor
34.349
-
  
Mr J Ford
0.012
-
  
Mr S A Hussain
1,959.639
-
  
Mr D S Redfern
718.082
-
  
Ms C Thomas
875.213
-
  
Mr P C Thomson
205.476
Mrs K Thomson
34.262
Dr P J T Vallance
988.774
-
  
Ms E Walmsley
802.125
-
  
 
 
The Company was advised of this information on 16 April 2014.
 
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
 
V A Whyte
Company Secretary
17 April 2014
  

 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: April 17, 2014 
 
 
By: VICTORIA WHYTE
------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc